Texas Nurse Loses DEA Power – No More Controlled Prescriptions
Published Date: 3/27/2025
Notice
Summary
Joely Keen, a nurse practitioner from Texas, lost her DEA registration because she no longer has the legal right to handle controlled substances in Texas. This means she can’t prescribe or manage certain medications anymore. The decision is final, effective immediately, and impacts her ability to work with controlled drugs, with no money penalties mentioned.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Joely Keen
The Drug Enforcement Administration revoked DEA Certificate of Registration No. MK4402210 issued to Joely Keen, A.P.R.N. Because her Texas APRN and registered nurse licenses are revoked and she lacks prescriptive authority, she cannot prescribe, administer, dispense, or otherwise handle controlled substances in Texas. The Order is effective April 28, 2025, and no monetary penalties are mentioned.
Pending Renewal and New Applications Denied
The Order denies any pending applications of Joely Keen to renew or modify DEA registration No. MK4402210 and denies any other pending application for additional DEA registration in Texas. This denial is made pursuant to 21 U.S.C. 823(g)(1) and 824(a) and is part of the revocation action effective April 28, 2025.
Opportunity to Seek Reconsideration
The Order notes that Respondent may dispute the factual finding that she lacks a Texas license by filing a properly supported motion for reconsideration of findings of fact within fifteen calendar days of the date of this Order. Any such motion and responses must be filed and served by email as specified.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-05163 — Thomas Andr'e Endicott, D.D.S.; Decision and Order
Thomas Andr'e Endicott, a dentist from Utah, lost his DEA registration because he no longer has permission to handle controlled substances in his state. Despite multiple attempts, he didn’t respond or ask for a hearing, so the DEA officially revoked his registration. This means he can’t legally prescribe or manage certain drugs anymore, effective immediately.
Next: 2025-05165 — Harvey Leslie, M.D.; Decision and Order
Dr. Harvey Leslie from Georgia lost his medical license earlier this year, so the DEA is officially taking away his permission to handle controlled substances. Since he didn’t ask for a hearing, the DEA’s decision is final, meaning he can no longer prescribe or manage these drugs. This change is immediate and affects Dr. Leslie’s ability to work with controlled medicines, with no money or appeals left on the table.